XRAY
DENTSPLY SIRONA Inc.11.37
-0.03-0.26%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A adds turnaround timelines
Q&A delivered execution timelines absent from prepared remarks, pinpointing commercial reorganization as complete with teams active by March-April, dealer expansions boosting CTS in late Q3/early Q4, and a $30 million H1 inventory sell-through headwind from drop-ship shifts. Debt paydown leads capital allocation before opportunistic buybacks at bargain prices, while premium pricing holds firm versus low-end rivals. Implants advance via focused sales and education, but DSOs and China remain exploratory beyond 2026. Reorg done fast. Management eyes U.S. positivity in Q4 to seed 2027 growth.
Key Stats
Market Cap
2.27BP/E (TTM)
-Basic EPS (TTM)
-4.40Dividend Yield
0.06%Recent Filings
8-K
Q4 sales up, loss from impairments
Dentsply Sirona posted Q4 net sales of $961M, up 6.2% reported but 2.5% constant currency, yet swung to a $146M net loss from $144M impairments in ortho/implants and connected tech. Restructuring targets $120M annual savings, redirecting to growth initiatives; dividend axed for debt paydown and buybacks. 2026 guides $3.5B-$3.6B sales, adjusted EPS $1.40-$1.50. Impairments signal U.S. volume weakness.
10-K
FY2025 results
Dentsply Sirona's FY2025 net sales fell 3.0% to $3.68B, or 4.3% on a constant currency basis, with Orthodontic and Implant Solutions plunging 12.6% y/y due to Byte aligner suspension while Wellspect Healthcare grew 6.6%. Q4 momentum faltered as CAD/CAM and implant volumes dropped amid U.S. competitive pressures and tariffs, though Essential Dental consumables held steady. Gross margins slipped 160bps to 50.0% from unfavorable mix; SG&A fell 10.4% on lower headcount and Byte marketing cuts. Net loss narrowed to $598M from $910M, driven by $650M in goodwill/intangible impairments (down from $1.0B). Operating cash flow halved to $235M; net debt rose to 59.9% of capitalization. No dividends declared post-Q4. Cyber incidents threaten DS Core platform momentum.
8-K
Board adds finance experts
Dentsply Sirona expanded its board from 11 to 13 directors, appointing James D. Forbes and Brian P. McKeon effective February 27, 2026, to bolster strategic oversight of its Return-to-Growth action plan. Forbes, a healthcare investment banking veteran, joins the Compensation & Human Capital Committee; McKeon, ex-CFO of IDEXX Laboratories, takes Audit and Finance and Science and Technology seats. Willie A. Deese will not seek reelection at the 2026 annual meeting. New blood sharpens financial edge.
8-K
Renews Patterson distribution deal
Dentsply Sirona renewed its non-exclusive U.S. dental equipment distribution agreement with Patterson Dental, announced January 14, 2026. This partnership expands access to key technologies like CEREC systems and Primescan scanners. Renewed ties fuel growth. Executives tout efficiency gains for practices.
8-K
Zurbay joins Dentsply board
Dentsply Sirona expanded its board from 10 to 11 members and appointed Donald Zurbay, ex-CEO of Patterson Companies, effective January 10, 2026; he joins the Audit and Finance Committee. Zurbay's dental industry expertise bolsters capital allocation and growth execution. Board forms Growth and Value Creation Committee to oversee Return-to-Growth plan. New oversight sharpens strategy focus.
IPO
Employees
Sector
Industry
ALC
Alcon Inc.
79.02-0.17
ALGN
Align Technology, Inc.
162.89+0.16
BDX
Becton, Dickinson and Company
196.39-3.70
HSIC
Henry Schein, Inc.
77.05-0.34
ISRG
Intuitive Surgical, Inc.
554.58-4.94
NVST
Envista Holdings Corporation
21.90-0.16
SOLV
Solventum Corporation
80.59-1.30
SONX
Sonendo, Inc.
0.20-0.07
TUTH
Standard Dental Labs Inc.
0.30-0.01
ZIMV
ZimVie Inc.
18.99+0.00